Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ARK Fintech Innovation ETF (ARKF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ARK Fintech Innovation ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while ARK Fintech Innovation ETF trades at $40.81. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | ARKF | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $58.82 |
52-Week Low | $20.06 | $36.14 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ARKF trades at $42.04, up 2.61% with strong technical momentum showing bullish signals across moving averages and oscillators. The stock faces resistance at $43-44 while finding support at $41-42 levels. Recent coverage highlights institutional interest in the fund's holdings, particularly in technology stocks favored by prominent investors.
The ETF's exposure to high-growth technology stocks positions it for potential upside, though elevated RSI levels suggest near-term consolidation risk. Investors face concentration risk in the fund's top holdings and market volatility sensitivity, requiring careful position sizing given the aggressive growth focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →
